Edition:
India

Ben Hirschler

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

17 Jul 2018

China heart drug sold globally may have had impurity since 2012

LONDON A common blood pressure and heart drug manufactured in bulk by a Chinese company and sold worldwide may have contained an impurity linked to cancer since 2012, European regulators said on Tuesday.

06 Jul 2018

Hitting cancer early: AstraZeneca's bid to outmanoeuvre rivals

LONDON AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

27 Jun 2018

AstraZeneca, Merck eye $1 billion boost from cancer drug success

LONDON AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

25 Jun 2018

Clamor for GSK shingles shot points to bigger profits

LONDON GlaxoSmithKline is facing "unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought.

21 Jun 2018

Key marijuana drug approval looms as cannabis goes mainstream

LONDON Evidence that cannabis can ease epilepsy and other conditions is building as a British company counts down to what would be the first U.S. government approval for a prescription drug derived from the marijuana plant.

20 Jun 2018

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

19 Jun 2018

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

ZURICH/LONDON Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.

31 May 2018

Another antibiotic crisis - fragile supply leads to shortages

LONDON Shortages of some life-saving antibiotics are putting growing numbers of patients at risk and fuelling the evolution of "superbugs" that do not respond to modern medicines, according to a new report on Thursday.

31 May 2018

Another antibiotic crisis: fragile supply leads to shortages

LONDON Shortages of some life-saving antibiotics are putting growing numbers of patients at risk and fuelling the evolution of "superbugs" that do not respond to modern medicines, according to a new report on Thursday.

30 May 2018

Gap in regulating biotech drug copies prompts WHO to step in

LONDON Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike - but uneven regulation has created a lopsided market.

Markets

  • Asia
  • U.S.
  • Europe
  • Sectors
Stock Search
Sensex 36,373.44 -146.52 -0.40%
Nikkei 22,794.19 + 96.83 +0.43%
Hang Seng 28,117.42 -64.26 -0.23%
EUR/INR 79.901 +0.16%
USD/INR 68.620 +0.29%
GBP/INR 89.535 -0.21%
Gold 1,223.90 -1.80 -0.15%
Oil 68.05 -0.03 -0.04%
Corn 347.00 +0.75 +0.22%